Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
PaperCitations, authors & open-access status
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 85 citations, 2024 year and hybrid oa status.
85
Citations
2024
Year
hybrid
OA Status